Gilead Sciences (GILD) Analysis

This report is auto-generated by an AI stock research platform for informational purposes only. The content is for general information and research reference, and does not constitute financial advice. Data may lag or be incomplete. Always conduct your own research and consult qualified professionals before making any financial decisions. # [Qiltrack AI] Gilead Sciences Inc (GILD) 3-Minute Overview ### 🎯 Layer 1: 30-Second Key Takeaways > **💡 One-Sentence Summary** > > Simply put, Gilead is a large, cash-generating biotech company that looks more like a steady pharmaceutical profit machine than a speculative biotech bet. > **📍 Basic Profile** > > Market Cap **$170.5 billion** · Biotechnology · NASDAQ NMS - GLOBAL MARKET · Price **$137.34** > **⚡ 3 Things You Should Know** > > 1. 💰 Cash Machine with Real Margins: Gilead’s gross margin is nearly 79% and net margin is close to 29%, which tells you this is not a “story stock” — it already throws off serious profits and cash. > > 2. 📈 Earnings Are Growing Faster Than Sales: Revenue growth over the last 3–5 years has only been low-single-digit, but EPS growth has been much stronger, meaning management has been improving profitability even without explosive top-line growth. > > 3. ⚠️ Not Cheap for a Slow Grower: At about 20x trailing earnings and trading in the upper part of its 52-week range, the market is no longer pricing Gilead like a sleepy defensive name — it’s betting margin expansion and pipeline execution continue. > **🎯 Quick Health Check** > > | Dimension | Rating | Details | > |-----------|--------|---------| > | Profitability | Strong💪 | Net margin 28.91%, gross margin 78.83% | > | Growth Rate | Steady📈 | Revenue growth 3Y CAGR 2.57% | > | Financial Health | Healthy💚 | Current ratio 1.55, interest coverage 44.73x | > | Valuation | Fair / Pricey | PE 20.03x | --- ### 📋 Layer 2: 2-Minute Deep Dive #### 📊 How Does This Company Make Money? **Business Model in One Sentence:** Gilead develops and sells branded biopharma treatments, mainly to healthcare systems, hospitals, and patients, making money through patented drug sales. **Revenue Breakdown:** | Business | Share | Trend | Comment | |----------|-------|-------|---------| | HIV therapies | [Data unavailable] | → | Historically the core franchise and likely still the profit backbone | | Oncology / Cell therapy / Other drugs | [Data unavailable] | ↑ | This is where investors look for the next leg of growth beyond legacy products | **Profitability Metrics:** | Metric | Value | Ranking | Interpretation | |--------|-------|---------|----------------| | Gross Margin | 78.83% | Top tier | Very high for healthcare, which usually means strong pricing power and valuable IP | | Net Margin | 28.91% | Top tier | Shows Gilead converts a large share of sales into bottom-line earnings | | ROE | 41.02% | Excellent>20% | Exceptionally strong, though helped in part by leverage and capital structure | --- #### 📈 How's the Growth? **Growth Assessment:** Steady Growth | Metric | Latest | vs Last Year | Trend | |--------|--------|--------------|-------| | Revenue Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Profit Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | **Growth Quality:** > What’s interesting is that the multi-year picture shows modest revenue growth but much stronger EPS growth. In other words, this is not a company growing by sheer volume alone — a lot of the progress appears to be coming from better mix, margins, and capital efficiency. That’s good, but it also means future upside depends a lot on execution, not just demand. --- #### 💰 Financial Health Check **One Sentence:** Think of it like someone with a very strong salary, manageable bills, and enough cash flow to comfortably handle debt. | Metric | Value | Safe Zone | Assessment | |--------|-------|-----------|------------| | Debt Ratio | [Data unavailable] | <60% safe | [Data unavailable] | | Current Ratio | 1.55 | >1.5 healthy | ✅Safe | | Cash Flow | Positive (cash flow/share TTM $6.68) | >0 | ✅Positive | Worth noting: debt-to-equity is 1.10, which is not tiny, but interest coverage of 44.73x says the company is nowhere near debt stress. --- #### 🏷️ Is It Expensive Now? **Price Position (based on 52-week range):** - 52-Week Low: $93.37 - 52-Week High: $157.29 - Current: $137.34, **very close to the high** | Position Range | Cheap Zone | Fair Zone | Pricey Zone | |----------------|------------|-----------|-------------| | Criteria | 0-33% | 33-66% | 66-100% | | **Current** | | | ●(68.8% position) | **Valuation Comparison:** | Comparison | Current | Reference | Assessment | |------------|---------|-----------|------------| | vs Own History | PE 20.03x | 5-year avg [Data unavailable] | [Data unavailable] | | vs Peers | PE 20.03x | Industry avg [Data unavailable] | [Data unavailable] | **What the Current Valuation is Betting On:** > Basically, the current price suggests the market believes Gilead can keep defending its core cash-generating drug portfolio while expanding earnings through newer products, pipeline execution, and margin discipline. If growth slips back to “just stable,” the stock may have less room to rerate higher. --- #### 📰 Any Recent News? | Date | Event | Impact | |------|-------|--------| | 2026-03-17 | Jefferies initiated/analysts highlighted Gilead with Buy-style bullishness and a $180 target | Positive — reinforces the idea that Wall Street sees further EPS and margin upside | | 2026-03-18 | Articles highlighted mixed recent returns and valuation debate | Neutral — sentiment is constructive, but investors are clearly questioning how much good news is already priced in | --- ### 📊 Layer 3: Want More? 3-Minute Complete Analysis #### I. Detailed Financial Data **Profitability Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Gross Margin | 78.83% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Net Margin | 28.91% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | ROE | 41.02% | [Data unavailable] | [Data unavailable] | [Data unavailable] | **Growth Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Revenue Growth | [TTM latest unavailable] | [Data unavailable] | [Data unavailable] | ↑ low-single-digit over 3Y CAGR 2.57% | | Profit Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | | EPS Growth | [TTM latest unavailable] | [Data unavailable] | [Data unavailable] | ↑ strong over 3Y CAGR 23.06% | --- #### II. Earnings Track Record **Last 4 Quarters vs Expectations:** | Quarter | EPS Expected | EPS Actual | Surprise | |---------|--------------|------------|----------| | 2025-12-31 | $1.85 | $1.86 | +0.73% Beat 😀 | | 2025-09-30 | $2.17 | $2.47 | +13.68% Beat 😀 | | 2025-06-30 | $2.00 | $2.01 | +0.60% Beat 😀 | | 2025-03-31 | $1.82 | $1.81 | -0.59% Miss 😟 | **Earnings Trend Interpretation:** Three beats in the last four quarters — including one meaningful upside quarter — suggest execution has been solid. It’s not a perfect streak, but it does tell you the business has generally been coming in a bit better than expected rather than disappointing the market. --- #### III. What the Market Thinks **Analyst Ratings:** | Rating | Count | Percentage | |--------|-------|------------| | Strong Buy/Buy | 30 firms | 78.9% | | Hold | 8 firms | 21.1% | | Sell | 0 firms | 0.0% | **Target Price:** [Data unavailable] ~ [Data unavailable] (Median [Data unavailable]) **vs Current Price:** [Data unavailable] **Insider Activity:** Net mixed, but recent disclosed transactions lean toward routine selling and equity-related awards rather than aggressive open-market buying > What you might care about is this: the recent insider records show small sales plus stock awards/exercise activity. That usually reads more like compensation management than a strong signal of conviction either way. --- #### IV. Key Risk Alerts **3 Risks to Watch:** 1. **Growth Durability Risk:** Revenue CAGR has only been in the low single digits → If newer products don’t offset slower legacy franchises, the stock could start looking expensive for its growth profile. 2. **Pipeline / Product Concentration Risk:** Like most large biopharma companies, a lot depends on continued success in key drug portfolios and new launches → If trial results or launches underwhelm, earnings expectations can reset quickly. 3. **Valuation Compression Risk:** The stock is trading in the pricey zone of its 52-week range → If sentiment cools or earnings momentum softens, multiple contraction could hurt returns even if the business stays fundamentally solid. --- ### 🎬 Summary & Next Steps > **📝 Three-Sentence Summary** > > **What it is:** Gilead is a mature, highly profitable biotech company with a pharma-like profile: strong cash flow, strong margins, and lower drama than many biotech names. > > **Key strength:** Its biggest advantage is that it already earns a lot of money — high margins, strong ROE, positive cash flow, and dependable earnings delivery give it a solid base. > > **Key risk:** The main concern is that revenue growth is not especially fast, so at around 20x earnings, the stock needs continued margin gains and pipeline execution to justify further upside. --- > **🔍 Want to Learn More?** > > • Want to know if this company has a strong moat? → Try【Buffett Mode】for deeper analysis > > • Want to check for hidden landmines? → Try【Muddy Mode】for risk screening > > • Is this a growth stock? Want to calculate if it's worth the bet? → Try【Musk Mode】for analysis